Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 19, 2022 08:00 ET | Source: Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals to Participate in the ThinkEquity Conference

EDISON, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
September 26, 2022 17:00 ET | Source: Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals to Participate in the Cantor Oncology, Hematology & HemeOnc Conference

EDISON, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
September 14, 2022 08:00 ET | Source: Hepion Pharmaceuticals, Inc.

Upcoming Presentation at Joint Meeting of ISBRA and ESBRA to Highlight Potential of Hepion Pharmaceutical’s Rencofilstat to Treat Alcohol-Related Liver Disease

EDISON, N.J., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
September 12, 2022 08:00 ET | Source: Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals Announces Initiation of Dosing in Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial

- Hepion Collaborates with HepQuant and Summit Clinical Research to Evaluate Rencofilstat’s Impact on Hepatic Function and Numerous NASH Functional Biomarkers - - F3 NASH Subjects will be Evaluated...
September 08, 2022 08:00 ET | Source: Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

EDISON, N.J., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
August 31, 2022 08:00 ET | Source: Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals Announces Initiation of Phase 2b ‘ASCEND-NASH’ Trial

- Hepion Screens First Subject in Biopsy-Confirmed F2/F3 NASH Study - - Subjects will be Evaluated on Three Doses of Rencofilstat for a One-year Period - EDISON, N.J., Aug. 31, 2022 (GLOBE...
July 22, 2022 16:15 ET | Source: Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals Announces Further Adjournment of Annual Meeting of Stockholders

EDISON, N.J., July 22, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven...
June 28, 2022 08:30 ET | Source: Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals Further Strengthens Board with Appointments of Accomplished Biopharmaceutical Executives, Mr. Anand Reddi and Dr. Kaouthar Lbiati

EDISON, N.J., June 28, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven...
June 24, 2022 16:15 ET | Source: Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders

EDISON, N.J., June 24, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven...
June 20, 2022 08:00 ET | Source: Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals Receives FDA Orphan Drug Status Designation for Rencofilstat for the Treatment of Hepatocellular Carcinoma

EDISON, N.J., June 20, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven...